Conflict of interest: J. S. is founder, employee, and shareholder in ReNeuron Limited, a stem cell therapy company with a development program in stroke therapy. K. M. receives research funding from ReNeuron Limited.
Stem cells in stroke treatment: the promise and the challenges
Article first published online: 19 JUN 2012
© 2012 The Authors. International Journal of Stroke © 2012 World Stroke Organization
International Journal of Stroke
Volume 7, Issue 5, pages 426–434, July 2012
How to Cite
Sinden, J. D. and Muir, K. W. (2012), Stem cells in stroke treatment: the promise and the challenges. International Journal of Stroke, 7: 426–434. doi: 10.1111/j.1747-4949.2012.00840.x
Funding: ReNeuron Limited.
- Issue published online: 19 JUN 2012
- Article first published online: 19 JUN 2012
- ReNeuron Limited
- chronic disease;
- functional imaging;
- ischemic stroke;
- stem cells;
Stroke, for some years now the neglected major indication in the pharmaceutical development cupboard, has recently become one of the hot areas for stem cell therapy development. This is driven by better understanding of potential therapeutic opportunities both in the acute and chronic phases and the launch of a series of new early phase clinical trials in a number of countries, driven by positive data in relevant animal models. In addition, the impetus for stem cell product development is motivated by patient demand, with thousands of victims seeking unproven treatments abroad. This article looks at the many challenges facing the development of a stem cell therapy for stroke. These range from product characterization and banking, through nonclinical safety and efficacy to the regulatory requirements for starting patient trials and beyond to maximizing value from carefully designed efficacy trials.